|32.84||-1.30||-3.81%||Vol 1.51M||1Y Perf -64.34%|
|Aug 9th, 2022 16:00 DELAYED|
|- -||-0.11 -0.33%|
|Target Price||75.73||Analyst Rating||Strong Buy 1.47|
|Potential %||130.60||Finscreener Ranking||★★★★+ 55.56|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★ 52.18|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★+ 61.36|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||19.59||Earnings Rating||Sell|
|Market Cap||3.19B||Earnings Date||3rd Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|5 Years||1 026.73%|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.86|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.57M|
|Avg. Monthly Volume||1.20M|
|Avg. Quarterly Volume||1.61M|
Fate Therapeutics Inc. (NASDAQ: FATE) stock closed at 34.14 per share at the end of the most recent trading day (a 2.15% change compared to the prior day closing price) with a volume of 2.01M shares and market capitalization of 3.19B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 279 people. Fate Therapeutics Inc. CEO is J. Scott Wolchko.
The one-year performance of Fate Therapeutics Inc. stock is -64.34%, while year-to-date (YTD) performance is -41.65%. FATE stock has a five-year performance of 1026.73%. Its 52-week range is between 17.1 and 97.43, which gives FATE stock a 52-week price range ratio of 19.59%
Fate Therapeutics Inc. currently has a PE ratio of -13.00, a price-to-book (PB) ratio of 4.84, a price-to-sale (PS) ratio of 59.64, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -25.22%, a ROC of -28.41% and a ROE of -33.75%. The company’s profit margin is -%, its EBITDA margin is -368.80%, and its revenue ttm is $49.71 Million , which makes it $0.51 revenue per share.
Of the last four earnings reports from Fate Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.86 for the next earnings report. Fate Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Fate Therapeutics Inc. is Strong Buy (1.47), with a target price of $75.73, which is +130.60% compared to the current price. The earnings rating for Fate Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Fate Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Fate Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.16, ATR14 : 2.87, CCI20 : 211.88, Chaikin Money Flow : 0.06, MACD : 1.47, Money Flow Index : 41.79, ROC : 2.40, RSI : 43.33, STOCH (14,3) : 60.76, STOCH RSI : 1.00, UO : 47.16, Williams %R : -39.24), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Fate Therapeutics Inc. in the last 12-months were: Bahram Valamehr (Option Excercise at a value of $712 349), Bahram Valamehr (Sold 288 340 shares of value $13 310 127 ), Cindy Tahl (Option Excercise at a value of $1 637 500), Cindy Tahl (Sold 276 314 shares of value $14 209 201 ), Edward J. Dulac (Option Excercise at a value of $615 384), Edward J. Dulac (Sold 24 704 shares of value $1 609 193 ), J. Scott Wolchko (Option Excercise at a value of $639 035), J. Scott Wolchko (Sold 264 968 shares of value $12 897 133 ), John D. Mendlein (Option Excercise at a value of $51 446), John D. Mendlein (Sold 32 926 shares of value $1 136 286 ), Karin Jooss (Sold 1 483 shares of value $33 842 ), Mark Plavsic (Sold 3 719 shares of value $91 525 ), Robert M. Hershberg (Sold 672 shares of value $15 288 ), Shefali Agarwal (Sold 1 648 shares of value $36 809 ), Timothy P. Coughlin (Sold 1 439 shares of value $32 824 ), Yu-Waye Chu (Option Excercise at a value of $367 200), Yu-Waye Chu (Sold 46 581 shares of value $2 165 884 )
Fri, 05 Aug 2022 03:37 GMT Fate Therapeutics (FATE) Receives a Hold from Robert W. Baird- TipRanks. All rights reserved.
Thu, 04 Aug 2022 02:26 GMT Fate Therapeutics (FATE) Receives a Buy from Mizuho Securities- TipRanks. All rights reserved.
Thu, 28 Jul 2022 09:25 GMT Fate Therapeutics (FATE) Initiated with a Hold at Needham- TipRanks. All rights reserved.
Thu, 19 May 2022 12:39 GMT Fate Therapeutics (FATE) Gets a Buy Rating from SVB Securities- TipRanks. All rights reserved.
Sun, 08 May 2022 15:10 GMT Fate Therapeutics (FATE) Has a New Rating from SVB Securities- TipRanks. All rights reserved.
Tue, 01 Mar 2022 13:50 GMT Fate Therapeutics (FATE) Receives a Hold from BMO Capital- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.